Our Leading IP Position
By filing our own IP in the US and Europe, and by licensing in available patents from world class academic, we are building a leadership IP position in the Christensenella space.
LNC Therapeutics filed proprietary patent families protecting christensenella modulation for therapeutic use. In September 2018, we acquired an exclusive licence for the Christensenella patents from Cornell University (Ithaca, NY, USA) covering the applications of Christensenella as a treatment for obesity and metabolic diseases. We’ve also had a number of patents granted by the USPTO.
We are actively scouting at the international level for patent licensing opportunities in order to continue expanding our intellectual property portfolio.